secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001437749-22-026611
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KemPharm Q3 net loss widens to $0.19/shr; cash $107.4M, runway into 2026
------------------------------------------------------------------------

- Net loss of $6.6M ($0.19/share) vs loss of $1.8M ($0.05) in Q3 2021; revenue $2.9M (+45% YoY).
- R&D expense $5.4M (up from $2.2M) on KP1077 and arimoclomol programs; G&A $4.0M (up from $1.9M).
- Cash and investments $107.4M as of Sep 30, 2022; based on current forecast, runway extends into 2026.
- Arimoclomol NDA resubmission for NPC expected as early as Q3 2023; ongoing FDA discussions.
- KP1077 Phase 2 trial in IH to initiate by year-end 2022; Phase 1 CV safety trial completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774922026611/0001437749-22-026611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774922026611/kmph20220904_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-026611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer